Exenatide (Byetta)

A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the GILA MONSTER lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used as an anti-diabetic and anti-obesity agent.

Also Known As:

Networked: 2013 relevant articles (364 outcomes, 600 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Han, Jenny: 25 articles (01/2020 - 09/2004)
2.	Hardy, Elise: 24 articles (12/2020 - 06/2016)
3.	Diamant, Michaela: 23 articles (01/2018 - 10/2006)
4.	Buse, John B: 22 articles (01/2020 - 07/2003)
5.	Greig, Nigel H: 20 articles (01/2020 - 03/2002)
6.	Holman, Rury R: 18 articles (01/2022 - 04/2016)
7.	Rosenstock, Julio: 18 articles (10/2021 - 05/2005)
8.	Hernandez, Adrian F: 17 articles (01/2022 - 04/2016)
9.	DeFronzo, Ralph A: 16 articles (01/2022 - 05/2005)
10.	Li, Yazhou: 16 articles (01/2021 - 01/2003)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 07/01/2015 - "In randomized, controlled trials, adjunctive exenatide ER 2 mg once weekly for 24-30 weeks significantly improved glycaemic control and reduced bodyweight in patients with inadequately controlled type 2 diabetes despite diet plus exercise and/or oral antihyperglycaemic drugs (OADs). " 03/01/2013 - "Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 led, in 66.8% of the population, to a statistically significant reduction in HbA(1c) levels in the first three-six months of the treatment; after 12 months of treatment, 25% of the population was still showing an improvement in HbA(1c) of > 2.0%. " 12/01/2020 - "In patients with type 2 diabetes, 24-week treatment with exenatide improved liver fat content in patients carrying PNPLA3 148I/I better than in patients with 148M/M. " 01/01/2009 - "The objective of this review is to discuss the available published evidence on exenatide therapeutic efficacy and tolerability, and the role of this new drug in the treatment of type 2 diabetes." 12/01/2005 - "Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?"
2.	Weight Loss (Weight Reduction) 01/01/2021 - "Future studies of OKV-119, configured to release exenatide for a longer extended months-long duration, are warranted to determine whether the combination of metabolic improvements and beneficial weight-loss, coupled with minimal impact on pet-owner's lifestyle, lead to improved outcomes for obese cats and feline DM patients." 01/01/2020 - "Our 24-week randomized, controlled, open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or usual care (CODEX) (n = 28), found exenatide was associated with significantly greater weight loss. " 04/01/2016 - "Weight reduction was significantly greater in Whites (P<0.0001 vs Asians), regardless of exenatide formulation. " 03/01/2016 - "Exenatide once weekly, like the twice-daily formulation, has been shown to improve glycemic parameters, promote weight loss, result in beneficial changes in cardiovascular risk factors, and is well-tolerated. " 01/01/2016 - "Exenatide and reference treatment led to a similar improvement in HbA1c (-0.7 ± 0.3% vs. -0.7 ± 0.4%; p = 0.29), whereas significant weight loss was observed only in the exenatide group (-5.5 ± 1.2 kg vs. -0.2 ± 0.8 kg; p = 0.001 for the difference between groups). "
3.	Body Weight (Weight, Body) 01/01/2007 - "At week 30, exenatide was associated with a significant reduction in mean (SD) body weight from baseline (-2.1 [0.2] kg), with progressive reductions after 2 years (-4.7 [0.3] kg; P < 0.001 vs baseline). " 01/01/2021 - "In diet-induced obese mice, EGLP-1 is more effective than exendin-4 in reducing body weight, reducing fat mass and improving hepatic steatosis. " 10/01/2021 - "Twice-daily administration of Ac3IV, or the gold standard control exendin-4, for 22 days, reduced energy intake as well as body weight and fat content. " 12/01/2014 - "Exenatide treatment of 26 weeks resulted in reduced body weight and improvement in certain cardiovascular risk markers and endothelial functions." 01/01/2016 - "Nine of the eleven studies showed significant decrease in body weight among participants in the exenatide group compared with placebo or control group while the other two studies did not report statistically significant differences in body weight. "
4.	Insulin Resistance 08/01/2012 - "Homeostasis model assessment of beta-cell function (HOMA-B) was not significantly increased, but the insulinogenic index and HOMA for insulin sensitivity (HOMA-S) were greatly improved in the exenatide group (P < 0.05). " 01/01/2016 - "Exenatide, compared with placebo, increased both OGTT- (P = 0.040) and clamp-based insulinogenic indexes (P = 0.016), improved insulin secretion in vitro (P = 0.041), but had no noticeable effect on insulin sensitivity (P = 0.405). " 09/01/2010 - "Thus, improved β-cell function rather than increased insulin sensitivity accounts for the bulk of HbA(1c) reduction following 6 months of exenatide treatment." 01/01/2006 - "Exendin-4 improved insulin sensitivity in ob/ob mice, as calculated by the homeostasis model assessment. " 12/01/2016 - "Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study."
5.	Obesity 11/17/2023 - "This study engineered the probiotic yeast Saccharomyces boulardii to produce Exendin-4 (Sb-Exe4) in the gastrointestinal tract of male C57BL/6 mice to combat diet-induced obesity. " 01/01/2020 - "A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity." 01/01/2018 - "In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo. " 01/01/2018 - "Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial." 11/01/2015 - "Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Metformin (Glucophage)
3.	Insulin (Novolin)
4.	Glucagon-Like Peptide 1 (GLP 1)
5.	Liraglutide
6.	Glucagon-Like Peptide-1 Receptor
7.	Insulin Glargine (Lantus)
8.	Blood Glucose (Blood Sugar)
9.	Pioglitazone (Actos)
10.	Lipids

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Injections
4.	Transplantation
5.	Subcutaneous Injections